Pfizer and BioNTech have received approval from the Paul-Ehrlich-Institut, the German Federal Institute for Vaccines and Biomedicine, to commence the first clinical trial of Covid-19 vaccine candidate
The German Institute for Vaccines and Biomedicine has approved Phase I/II clinical trial of Covid-19 vaccine candidate BNT162, developed jointly by Pfizer and BioNTech.
This is Germany’s first clinical trial of a Covid-19 vaccine candidate and is part of a global development programme. Pfizer and BioNTech have announced trials will also begin in the United States once regulatory approval is received, which is expected shortly.
‘Pfizer and BioNTech’s partnership has mobilised our collective resources with extraordinary speed in the face of this worldwide challenge. Now that the work in Germany can commence, we are looking forward to and actively preparing for the potential start of this unique and robust clinical study programme in the United States in the near future’, said Albert Bourla, Pfizer chairman and CEO.
‘This is a crisis right now, and a solution is desperately needed by all’, Bourla noted, adding that a vaccine should be ready to use by the autumn if all went according to plan.